Claim Missing Document
Check
Articles

Found 2 Documents
Search

Scoping Review: Pola Penggunaan Antipsikotika Pada Pasien Skizofrenia Paranoid Cotama, Cahana Rastra; Yulistiani
Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Vol. 12 No. 2 (2025): October
Publisher : Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v12i2.7330

Abstract

Paranoid schizophrenia has a better prognosis than other forms. The main sign of paranoid schizophrenia is having strong delusions or auditory hallucinations. This review article is prepared to study the patterns of antipsychotic treatment in schizophrenia patients. The literature sources include PubMed and Google Scholar over the past decade. The PICO screening procedure yielded 6 publications utilized as primary data. This review's findings suggest that the principal objective of antipsychotic treatment in people with schizophrenia is to attain remission swiftly and safely. Atypical antipsychotics are the primary treatment option for schizophrenia, specifically Risperidone, Aripiprazole, Olanzapine, Quetiapine, and Clozapine. The implementation of combination therapy is contingent upon the severity of schizophrenia symptoms. Using combinations of antipsychotics will lead to a wider range of receptor targets, which will make antipsychotics work better. In combination therapy, typical antipsychotics are utilized due to their swift alleviation of positive symptoms, including hallucinations and delusions. Paranoid schizophrenia for achieving early remission is capable of utilizing atypical monotherapy, combination of typical and atypical, combination of atypical and atypical antipsychotics in reaching remission with symptom assessments using PANSS and GAF.
Increasing traceability of halal medicine consumption through integrated data mining and digital payment in Indonesia: an approach Haq, Avip Zain; Cotama, Cahana Rastra
Journal of Halal Product and Research Vol. 8 No. 2 (2025): Advancing the Halal Industry: Innovation, Sustainability, and Global Impact
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jhpr.vol.8-issue.2.124-134

Abstract

Indonesia is a country with a Muslim population of 249,82 million (87.2%) in 2023. The potential of this large Muslim population is believed to drive a great demand for halal products. Based on the results of a national-scale drug update survey in Indonesia in 2019, the total number of drugs circulating in 34 provinces was 97,759 drug items, with data on the number of drugs registered in the Food and Drug Supervisory Agency (BPOM) registration of 14,263 drug items, due to the condition of the Indonesian pharmaceutical market, which is worth around USD 10.11 billion in 2021 and is estimated to reach USD 27 billion or more in 2035. This study aimed to develop an integrated data mining model that involves actors in the medical services sector and their digitalization systems, to improve downstream tracking of halal drug consumption. More than 50 articles were collected and analysed to create an integrated data mining model approach. This economic digitalization of digital payment can be the key to increasing traceability of halal drug consumption in Indonesia. The collected transaction data model contains halal-certified and non-halal medicines along with transaction details. Combined with data collection from various sources, such as medical records and BPJS data, it can complete the overall tracing of drug consumption on the downstream side. The results of this data integration can be measured and become an evaluation of drug consumption patterns in health facilities for patients   Keywords: Traceability, Halal Medicine, Data Mining, Digital Payment